ASH

News
Argenx_image

ASH: Argenx cues up a second use for efgartigimod

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a